期刊论文详细信息
Frontiers in Pharmacology
Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
Pharmacology
Paola Mian1  Patrick F. van Rheenen2  Marleen Bouhuys2 
[1] Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, Netherlands;Department of Pediatric Gastroenterology, Hepatology and Nutrition, Beatrix Children’s Hospital, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands;
关键词: ustekinumab;    therapeutic drug monitoring;    Crohn’s disease;    inflammatory bowel disease;    pediatrics;   
DOI  :  10.3389/fphar.2023.1180750
 received in 2023-03-06, accepted in 2023-09-11,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

Background: Ustekinumab is used off-label in pediatric Crohn’s disease refractory to anti-tumor necrosis factor. Data on optimal dosing, target trough levels, and potential benefit of therapeutic drug monitoring in children treated with ustekinumab are limited.Materials and Methods: We describe a series of six adolescents who consented to be treated with ustekinumab. We measured their trough levels, C-reactive protein, and fecal calprotectin before every administration.Results: Standard adult dosing was effective to achieve biochemical remission (fecal calprotectin < 250 mg/kg) in one patient and clinical remission (resolution of symptoms) in another. The other four patients failed to respond on standard dosing and underwent intravenous re-induction and interval shortening to increase ustekinumab trough levels. This resulted in biochemical remission in one patient and clinical remission in another, suggesting an exposure–response relationship. The remaining two patients had no therapeutic benefit, and ustekinumab was discontinued.Conclusion: In this report, we show that ustekinumab can induce remission in pediatric patients with anti-tumor necrosis factor refractory Crohn’s disease. It is worth escalating the dose before abandoning the drug as ineffective. Prospective studies in children are needed to determine long-term efficacy of ustekinumab, usefulness of therapeutic drug monitoring strategies, and, if applicable, optimal target trough levels.

【 授权许可】

Unknown   
Copyright © 2023 Bouhuys, Mian and van Rheenen.

【 预 览 】
附件列表
Files Size Format View
RO202310124037448ZK.pdf 1046KB PDF download
  文献评价指标  
  下载次数:2次 浏览次数:0次